DIAMOND: Patiromer Successful in Managing Hyperkalemia in Patients Receiving RAASi For HFrEF – American College of Cardiology -

The majority of patients with heart failure with reduced ejection fraction (HFrEF) and renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia had significantly lower K+ levels when taking patiromer compared with a placebo, based on findings from the DIAMOND trial presented April 3 at ACC.22. The trial initially screened 1,642 patients with HFrEF and either a history...

123456

PAYAL KOHLI, MD, FACC

Read the full article here

See more from Payal Kohli